摘要
目的观察阿莫西林克拉维酸钾干混悬剂对感染引起的新生儿高胆红素血症的治疗效果并进行成本分析。方法将2006年1月-2008年3月皖南医学院附属池州医院因感染所致新生儿高胆红素血症新生儿104例患儿随机分为观察组和对照组两组。观察组予口服阿莫西林克拉维酸钾干混悬剂抗感染治疗,而对照组予阿洛西林静脉点滴治疗,两组患儿均予蓝光光疗等综合退黄治疗措施。观察两组患儿治疗效果,采用最小成本分析法对两组进行评价。结果两组患儿在痊愈率、有效率、药物不良反应发生率、疗程及住院费用方面差异无统计学意义(P>0.05);观察组在药品费用、总成本及成本-效果比方面较对照组差异有统计学意义(P<0.01)。结论口服阿莫西林克拉维酸钾干混悬剂对感染引起的新生儿高胆红素血症相对于静脉应用阿莫西林具有明显的药物经济学优势。
Objective To explore the therapeutic effect and cost of clavulanic acid-amoxicillin on hyperbilirubinemia of newborn caused by infection.Methods A total of 104 neonates with hyperbilirubinemia caused by infection in our hospital from Jan.2006 to Mar.2008 were randomly divided into 2 groups：control group（n=52）and observed group（n=52）.The observed group received clavulanic acid-amoxicillin（per os）,while the control group received azlocillin（intravenous drip）.The clinical and economic effects of the two schemes were evaluated by cost-minimization analysis.Results There were no significant difference were found between the two group in cure rate,effective power,the incidence of adverse drug reactions,course of treatment and cost of hospitalization（P0.05）.The cost of drug,the total cost and the cost effectiveness ratios had statistical difference between the two groups（P0.01）.Conclusion The clavulanic acid-amoxicillin for oral use has marked pharmacoeconomics advantage over azlocillin（intravenous drip）for hyperbilirubinemia of newborn caused by infection.
出处
《中华全科医学》
2010年第8期951-952,共2页
Chinese Journal of General Practice
基金
安徽省池州市科技计划项目(ZC09012)
